Solanezumab study fails to meet primary goal

Eli Lilly and Co.'s EXPEDITION3 clinical study involving solanezumab failed to meet its primary goal in treating Alzheimer’s.
"The results of the solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer's disease," Eli Lilly President, Chief Executive Officer and Chairman Dr. John Lechleiter said. "We will evaluate the impact of these results on the development plans for solanezumab and our other Alzheimer's pipeline assets."
The patients involved in the study that were dosed with solanezumab did not show significant slowing in cognitive decline when comparing them to the patients who were dosed with the placebo. Many of the secondary goals of the trial were met, however.
"Lilly is grateful for the dedication of the patients, their families, and the clinical investigators who participated in this study," Eli Lilly Executive Vice President of Science and Technology and Research Laboratories President Jan Lundberg said. "Lilly remains committed to Alzheimer's research as we have been for nearly 30 years, and our portfolio includes many other promising approaches."